In order to broaden the activity of AZD0466, we tested clinically relevant standard of care as well as targeted therapies in combination with AZD0466 in DLBCL models with limited Bcl-2 inhibitor single agent activity. The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.